1- isoquinolin- 5- yl- 3- (4- trifluoromethyl- benzyl)- urea

07/01/2005 - "A-425619 was also effective in models of inflammatory pain and postoperative pain. "
10/31/2008 - "1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea (A-425619), a novel, potent, and selective transient receptor potential type V1 (TRPV1) antagonist, attenuates pain associated with inflammation and tissue injury in rats. "
07/01/2005 - "Taken together, the present data indicate that A-425619, a potent and selective antagonist of TRPV1 receptors, effectively relieves acute and chronic inflammatory pain and postoperative pain."
03/01/2009 - "A series of experiments incorporating 1:1, 3:1, or 0.3:1 ED(50) dose-ratio combinations of A-840257 and A-803467, or A-425619 and A-803467 were performed in both pain models, and the effective doses of mixtures that produced 50% antinociception (ED(50, mix)) were determined by isobolographic analysis. "
07/01/2005 - "A-425619 potently reduced complete Freund's adjuvant-induced chronic inflammatory pain after oral administration (ED50 = 40 micromol/kg p.o.) and was also effective after either i.t. "

07/01/2005 - "Furthermore, A-425619 maintained efficacy in the postoperative pain model after twice daily dosing p.o. "
07/01/2005 - "A-425619 was also effective in models of inflammatory pain and postoperative pain. "
07/01/2005 - "Taken together, the present data indicate that A-425619, a potent and selective antagonist of TRPV1 receptors, effectively relieves acute and chronic inflammatory pain and postoperative pain."

06/01/2010 - "The heat hypersensitivity was completely reversed by the TRPV1 antagonist A-425619. "
09/22/2011 - "In the present study, inhibition of the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1) with the selective antagonist A-425619 reversed the mechanical sensitization at both primary afferent terminals and isolated somata, and markedly attenuated mechanical behavioral hypersensitivity. "

01/01/2006 - "To further understand the peripheral mechanisms of TRPV1-related antinociception, we examined the effects of systemic and site-specific injections of A-425619 on evoked and spontaneous firing of spinal wide dynamic range (WDR) neurons in uninjured rats and rats with peripheral inflammation (CFA; 48 h). "
10/31/2008 - "1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea (A-425619), a novel, potent, and selective transient receptor potential type V1 (TRPV1) antagonist, attenuates pain associated with inflammation and tissue injury in rats. "
07/01/2005 - "A-425619 [1-isoquinolin-5-yl-3-(4-trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats."

07/01/2005 - "In vivo, A-425619 dose dependently reduced capsaicin-induced mechanical hyperalgesia (ED50 = 45 micromol/kg p.o.). "
01/01/2006 - "Systemic administration of A-425619, a potent and selective TRPV1 receptor antagonist that does not readily enter the CNS, produces antinociception in several rat models of pathological nociception, including complete Freund's adjuvant (CFA)-induced thermal hyperalgesia. "